Skip to main content

Table 2 Baseline characteristics

From: Clinical evaluation of a combination therapy of imepitoin with phenobarbital in dogs with refractory idiopathic epilepsy

Parameter Dimension Cohort A Cohort B Cohort C Group comparison
Seizure activity related parameter
Duration of epilepsy at inclusion in days Geometric Mean (95% CI) 642 (372–1110) 556.6 (313–991) 292.1 (93–915) p = 0.3341
Mean ± SEM 950 ± 183 755 ± 180 512 ± 193  
Monthly seizure frequency (MSF) Geometric Mean (95% CI) 4.06 (2.93-5.61) 3.73 (1.79-7.77) 3.54 (2.45-5.10) p = 0.6021
Monthly cluster day (MCD) Geometric Mean (95% CI) 0.62 (0.26-1.31) 0.48 (0.10-1.37) 0.51 (0.10-1.53) p = 0.7321
Animals with cluster in baseline or history m/n (%) 14/16 (87.5%) 6/11 (54.5%) 6/7 (85.7%) p = 0.1133
Animals with status in baseline or history m/n (%) 4/16 (25%) 1/11 (9.1%) 2/7 (28.6%) p = 0.5093
Animals without cluster or status in baseline or history m/n (%) 2/16 (12.5%) 5/11 (45.5%) 1/7 (14.3%) p = 0.1133
Medication related parameter
Dose of phenobarbital (A, B) or imepitoin (C) at inclusion in mg/kg per day Mean ± SEM Range 9.49 ± 0.59 5.0-13.2 8.16 ± 0.59 4.0-11.4 55.0 ± 4.30 40.0-76.0 p = 0.1382
Frequency of dogs with KBr at inclusion m/n (%) 7/16 (43.8%) 2/11 (18.2%) 0/7 (0%) p = 0.0693 p = 0.1664
Frequency of dogs with any 2ndpermanent antiepileptic at inclusion m/n (%) 9/16 (56.3%) 3/11 (27.3%) 0/7 (0%) p = 0.0273 p = 0.1374
Frequency of dogs with levetiracetam pulse therapy in baseline m/n (%) 1/16 (6.3%) 4/11 (36.4%) 2/7 (28.6%) p = 0.1383 p = 0.0484
Add-on dose of imepitoin (A, B) or phenobarbital (C) at inclusion (mg/kg per day) Mean ± SEM Range 23.5 ± 1.44 17.6-40.0 10.8 ± 0.47 8.6-14.8 1.2 ± 0.06 0.9-1.4  
  1. 1Analysis of variance, with Bonferroni's multiple comparison test
  2. 2t-Test comparing cohort A and B 3Chi-Square test comparing cohorts A, B and C 4Chi-Square test comparing cohort A and B